Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Switzerland,Netherlands,Poland,Sweden,Mexico,Australia,Spain,France,Belgium,Germany
Trial Manager
MAJ Il y a 5 ans
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Korea, Republic of
,
Mexico
,
Netherlands
,
Poland
,
Portugal
,
Saudi Arabia
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
Turkey
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids
The purpose of this study is to focus on potential differences in the occurrence of new-onset Diabetes Mellitus (a glucose metabolism disorder) when two different regimens of immunosuppressive treatment are compared.
Pays
Australia
,
Belgium
,
Colombia
,
Czech Republic
,
Estonia
,
Finland
,
France
,
Germany
,
Hungary
,
Italy
,
Korea, Republic of
,
Latvia
,
Lithuania
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Russian Federation
,
Slovakia
,
Spain
,
Sweden
,
Switzerland
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1